Market Cap | 1.63B | P/E | - | EPS this Y | -12.50% | Ern Qtrly Grth | - |
Income | -201.4M | Forward P/E | -10.32 | EPS next Y | 52.80% | 50D Avg Chg | - |
Sales | 520k | PEG | -2.38 | EPS past 5Y | - | 200D Avg Chg | 18.00% |
Dividend | N/A | Price/Book | 4.99 | EPS next 5Y | 5.00% | 52W High Chg | -17.00% |
Recommedations | 1.70 | Quick Ratio | 3.61 | Shares Outstanding | 593.13M | 52W Low Chg | 64.00% |
Insider Own | 0.09% | ROA | -28.94% | Shares Float | 515.43M | Beta | 0.48 |
Inst Own | 74.17% | ROE | -60.04% | Shares Shorted/Prior | 44.66M/54.12M | Price | 3.20 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 5,610,301 | Target Price | 7.29 |
Oper. Margin | -18,465.13% | Earnings Date | May 2 | Volume | 2,355,788 | Change | -0.31% |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Needham | Buy | Jul 26, 24 |
Barclays | Overweight | Jun 11, 24 |
Barclays | Overweight | Jun 10, 24 |
Stifel | Buy | Jun 10, 24 |
Needham | Buy | Jun 7, 24 |
Wedbush | Outperform | Jun 7, 24 |
Needham | Buy | May 2, 24 |
Baird | Neutral | Apr 30, 24 |
TD Cowen | Buy | Apr 29, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
O'Farrell Elizabeth G. | Director Director | Aug 24 | Buy | 2.28 | 13,186 | 30,064 | 26,220 | 08/24/23 |
LAWLIS V BRYAN | Director Director | May 11 | Sell | 3 | 35,000 | 105,000 | 05/11/23 | |
LAWLIS V BRYAN | Director Director | May 11 | Option | 1.1 | 35,000 | 38,500 | 35,000 | 05/11/23 |
Molineaux Susan | Director Director | May 01 | Sell | 2.48 | 35,000 | 86,800 | 05/01/23 | |
Molineaux Susan | Director Director | May 01 | Option | 1.1 | 35,000 | 38,500 | 35,000 | 05/01/23 |
GRETHLEIN ANDREW J | EVP, Chief Operating.. EVP, Chief Operating Officer | Feb 09 | Sell | 3.03 | 384,719 | 1,165,699 | 02/10/23 | |
GRETHLEIN ANDREW J | EVP, Chief Operating.. EVP, Chief Operating Officer | Feb 09 | Option | 1.51 | 150,000 | 226,500 | 384,719 | 02/10/23 |
Bloom Olivia Kyusuk | EVP, Chief Financial.. EVP, Chief Financial Officer | Feb 08 | Sell | 3.08 | 400,000 | 1,232,000 | 74,588 | 02/10/23 |
Bloom Olivia Kyusuk | EVP, Chief Financial.. EVP, Chief Financial Officer | Feb 08 | Option | 1.51 | 400,000 | 604,000 | 474,588 | 02/10/23 |
SCARLETT JOHN A | Chairman, President.. Chairman, President and CEO | Feb 08 | Sell | 3.04 | 1,340,000 | 4,073,600 | 02/10/23 | |
SCARLETT JOHN A | Chairman, President.. Chairman, President and CEO | Feb 08 | Option | 1.5 | 1,340,000 | 2,010,000 | 446,668 | 02/10/23 |
EASTHAM KARIN | Director Director | Jan 13 | Option | 1.10 | 35,000 | 38,500 | 109,047 | 01/17/23 |
GRETHLEIN ANDREW J | EVP, Chief Operating.. EVP, Chief Operating Officer | Sep 12 | Option | 1.7 | 234,719 | 399,022 | 234,719 | 09/14/22 |
EASTHAM KARIN | Director Director | Apr 20 | Option | 1.41 | 35,000 | 49,350 | 74,047 | 04/21/22 |